Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Kraig Biocraft Laboratories, Inc.
- Market Cap
- Unavailable
- Price
- $0.093
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.65%
- Volume
- 420.2K
About
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. The company’s products are used in performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, and other applications; military and police for its ballistic protection; and geotextiles, safe and protective clothing, textiles used in transportation and buildings, and functional and sportive textiles. Kraig Biocraft Laboratories, Inc. was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
Quick stats
Shares outstanding—
Computed float850.7M
Float / sharesUnknown
Key info
SectorIndustrials
IndustryManufacturing - Textiles
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001413119
Websitehttps://www.kraiglabs.com
AI Summary
AI-generated1/24
minorneutralother
Kraig Biocraft Laboratories CEO Kim Thompson Publishes Thought Leadership Article on the Next Chapter of Authored Biology in Biocompare
Kraig Labs CEO Kim Thompson published a thought leadership article in Biocompare titled "Beyond Therapeutics," introducing the concept of "authored biology" to describe the manufacturing potential of synthetic biology.
The article uses Kraig Labs' experience scaling recombinant spider silk to argue that the next era of the industry will be defined by the ability to manufacture materials at commercial scale rather than just discovery.
Additionally, the company noted its recent feature on the cover of National Geographic's March 2026 issue as evidence of its leadership in biomaterials.